Cargando…
Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. T...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094768/ https://www.ncbi.nlm.nih.gov/pubmed/21593964 http://dx.doi.org/10.1371/currents.RRN1236 |
_version_ | 1782203602740183040 |
---|---|
author | Nguyen, Christine M. Mendes, Margaret A.S. Ma, Joseph D. |
author_facet | Nguyen, Christine M. Mendes, Margaret A.S. Ma, Joseph D. |
author_sort | Nguyen, Christine M. |
collection | PubMed |
description | Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. Thiopurine drugs are metabolized, in part, by thiopurine methyltransferase (TPMT). TPMT displays genetic polymorphism resulting in null or decreased enzyme activity. At least 20 polymorphisms have been identified, of which, TPMT *2, *3A, *3B, *3C, and *4 are the most commonly studied. These polymorphisms have been associated with increased myelosuppression risk. TPMT genotyping may be useful to predict this risk. |
format | Text |
id | pubmed-3094768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30947682011-05-17 Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk Nguyen, Christine M. Mendes, Margaret A.S. Ma, Joseph D. PLoS Curr Evidence on Genomic Tests Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. Thiopurine drugs are metabolized, in part, by thiopurine methyltransferase (TPMT). TPMT displays genetic polymorphism resulting in null or decreased enzyme activity. At least 20 polymorphisms have been identified, of which, TPMT *2, *3A, *3B, *3C, and *4 are the most commonly studied. These polymorphisms have been associated with increased myelosuppression risk. TPMT genotyping may be useful to predict this risk. Public Library of Science 2011-05-15 /pmc/articles/PMC3094768/ /pubmed/21593964 http://dx.doi.org/10.1371/currents.RRN1236 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Evidence on Genomic Tests Nguyen, Christine M. Mendes, Margaret A.S. Ma, Joseph D. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk |
title | Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk |
title_full | Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk |
title_fullStr | Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk |
title_full_unstemmed | Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk |
title_short | Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk |
title_sort | thiopurine methyltransferase (tpmt) genotyping to predict myelosuppression risk |
topic | Evidence on Genomic Tests |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094768/ https://www.ncbi.nlm.nih.gov/pubmed/21593964 http://dx.doi.org/10.1371/currents.RRN1236 |
work_keys_str_mv | AT nguyenchristinem thiopurinemethyltransferasetpmtgenotypingtopredictmyelosuppressionrisk AT mendesmargaretas thiopurinemethyltransferasetpmtgenotypingtopredictmyelosuppressionrisk AT majosephd thiopurinemethyltransferasetpmtgenotypingtopredictmyelosuppressionrisk |